Views

CrossRef citations to date

Altmetric

Letters to the Editor

PECAM is an effective and safe anthracycline-containing third-line regimen for patients with relapsed or refractory non-Hodgkin lymphoma

Fumi NakamuraDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Honoka AraiDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Katsuya TokitaDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Shiho FuruichiDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Fusako Sugita-NagasawaDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Wataru TakahashiDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Tomoyuki HandaDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Hisako IsoDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Jiro TadokoroDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Shigeharu TsurumiDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Yuko NakamuraDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Yuka NakamuraDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Ko SasakiDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Sachiko SeoDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Motoshi IchikawaDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan

Kinuko MitaniDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, JapanCorrespondence[email protected]

show all

Click to increase image sizeClick to decrease image size

Disclosure statement

Dr. Seo reports personal fees from Janssen Pharmaceutical K.K., outside the submitted work.　 Dr. Ichikawa reports personal fees from Novartis Pharma, personal fees from Takeda Pharmaceutical, personal fees from Janssen Pharmaceutical, personal fees from Nippon Shinyaku, personal fees from Bristol-Myers Squibb, personal fees from Kyowa Kirin, outside the submitted work. Dr. Mitani reports grants from Kyowa Kirin, grants from Chugai, grants from Nihon Pharm., grants from Taiho, grants from MSD, grants from Daiichi-Sankyo, grants from Pfizer, from Astellas, grants from Takeda, grants from Teijin, grants from Sumitomo Dainippon, outside the submitted work.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

PECAM is an effective and safe anthracycline-containing third-line regimen for patients with relapsed or refractory non-Hodgkin lymphoma

Information for

Open access

Opportunities

Help and information

PECAM is an effective and safe anthracycline-containing third-line regimen for patients with relapsed or refractory non-Hodgkin lymphoma

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature